Axim Biotechnologies, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
AXIM Biotechnologies saw revenue growth in Q2 2024 compared to the previous year, but continues to operate with a significant net loss and negative working capital.
OID
AXIM Biotechnologies reports increased revenue but continues to operate at a loss in Q1 2024, shifting strategic focus to commercializing its Dry Eye Disease (DED) diagnostic system.
OID
10-Q: AXIM Biotechnologies Reports Q1 2024 Financial Results, Focuses on Dry Eye Disease Diagnostics
AXIM Biotechnologies reports increased revenue but continues to operate at a loss in Q1 2024, prioritizing its Dry Eye Disease diagnostic program.